Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| EpCAM 2.5% EpCAM-negative | 90.7% | IHC, high-level EpCAM expression (TMA, n=473) | doi.org |
| FAP | >85% | Stromal FAP | Wikipedia |
| CEACAM5 | 50-60% | IHC, any expression | Wikipedia |
| Claudin 18.2 SPOTLIGHT/GLOW screening | 35-40% | IHC 2+/3+ in >=75% of cells (zolbetuximab definition) | Wikipedia |
| WRN helicase (MSI-high cancers) | 20% | MSI-H | |
| HER2 ToGA screening | 15-20% | IHC 3+ or 2+/ISH+ | Wikipedia |
| FGFR2 FORTITUDE-101 selected IHC 2+/3+ | 3-8% | FGFR2b overexpression/amplification | cBioPortal (TCGA) |
| MET | 2-5% | Amplification | cBioPortal (TCGA) |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
6 cell lines, 0 mouse models and 7 repositories are listed for this cancer. See them →